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Background: Inflammatory cytokines and transforming growth factor-β (TGF-β) are mutually inhibitory. However,
hyperactivation of nuclear factor-κB (NF-κB) and TGF-β signaling both emerge in glioblastoma. Here, we report
microRNA-148a (miR-148a) overexpression in glioblastoma and that miR-148a directly suppressed Quaking (QKI), a
negative regulator of TGF-β signaling.
Methods: We determined NF-κB and TGF-β/Smad signaling activity using pNF-κB-luc, pSMAD-luc, and control plasmids.
The association between an RNA-induced silencing complex and QKI, mitogen-inducible gene 6 (MIG6), S-phase
kinase–associated protein 1 (SKP1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was tested
with microribonucleoprotein immunoprecipitation and real-time PCR. Xenograft tumors were established in the
brains of nude mice.
Results: QKI suppression induced an aggressive phenotype of glioblastoma cells both in vitro and in vivo. Interestingly,
we found that NF-κB induced miR-148a expression, leading to enhanced-strength and prolonged-duration TGF-β/Smad
signaling. Notably, these findings were consistent with the significant correlation between miR-148a levels with NF-κB
hyperactivation and activated TGF-β/Smad signaling in a cohort of human glioblastoma specimens.
Conclusions: These findings uncover a plausible mechanism for NF-κB–sustained TGF-β/Smad activation via miR-148a in
glioblastoma, and may suggest a new target for clinical intervention in human cancer.
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Glioblastoma multiforme (GBM) is the most common
and lethal primary brain tumor in adults; it has a
spectrum of aberrantly aggressive phenotypes [1]. Al-
though non-metastasizing, and the despite advances in
treatments over the past decades, the extensive invasion
of GBM limits patient survival to approximately 12–14
months [2,3]. The extremely poor prognosis of patients
with GBM is due to the ability of GBM to diffusely infil-
trate the cerebral cortex, which limits the extent of
surgical resection and high-dose radiotherapy for fear of
unacceptable permanent neurological damage to the
patient. Poor blood–brain barrier penetration, intrinsic
GBM resistance, and nonselective toxicity restrict the* Correspondence: doctorwanghui@126.com
†Equal contributors
1Department of Neurosurgery, The Third Affiliated Hospital, Sun Yat-Sen
University, 600 Tian He Road, Tian He District, Guangzhou, Guangdong
510630, China
Full list of author information is available at the end of the article
© 2015 Wang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.value of traditional chemotherapy [4]. Therefore, the de-
velopment of improved therapies rests on further under-
standing of the molecular mechanism of the aggressive
malignant phenotype of GBM. However, this remains
largely unclear.
Transforming growth factor-β (TGF-β) is a multifunc-
tional polypeptide that can switch from being a tumor
suppressor in normal or dysplastic cells to a tumor pro-
moter in advanced cancers [5-7]. Although TGF-β is a
notable tumor suppressor in most cases, it promotes
proliferation, invasion, metastasis, and intratumoral angio-
genesis in non-epithelial cancer such as glioma [8-15].
Interestingly, TGF-β usually suppresses nuclear factor-κB
(NF-κB) activity in normal cells, and NF-κB activation
induces Smad7 expression, which in turn inhibits TGF-β
signaling through Smads [16,17]. However, NF-κB and
TGF-β pathway activation both emerge in glioma [18].
This indicates the possibility of cross-talk between NF-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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poorly understood.
The RNA-binding protein Quaking (QKI) belongs to
the signaling transduction and activation of RNA
(STAR) protein family [19]. The three QKI isoforms,
QKI-5, QKI-6, and QKI-7, which share an RNA-binding
hnRNPK homology (KH) domain, can dimerize with one
another and shuttle between the cytoplasm and the nu-
cleus [20,21]. The QKI gene is implicated as being im-
portant in schizophrenia, and QKI controls the
translation of many oligodendrocyte-related genes
[22,23]. QKI expression is also a characteristic of glial
progenitors, and a high frequency of deletion of chromo-
some 6q26-27, containing QKI, was observed in anaplas-
tic astrocytoma and GBM [24-27]. Chen and team
validated the finding that QKI suppresses GBM by
stabilizing microRNA-20a (miR-20a), which targets
TGF-β receptor 2 (TGFβR2) [28]. The potential import-
ance of QKI in GBM pathogenesis is elevated further by
its direct regulation by the tumor suppressor TP53 [29].
However, the frequency of TP53 mutations is about 70%
in GBM [30], which means that TP53 may not regulate
QKI in most cases. Taken together, we suspect that there
may be an alternative regulatory mechanism of QKI
protein expression in GBM.
Being able to coordinately regulate target gene reper-
toires, miRNAs can potentially modulate multiple steps
of cancer development and progression [31,32]. From
analysis using a published microarray-based high-
throughput assessment, we found that miR-148a expres-
sion is significantly higher in GBM tissues than in normal
brain tissue. Herein, we report that miR-148a was induced
by NF-κB and directly targeted and suppressed the 3′ un-
translated regions (3′ UTRs) of multiple genes that func-
tion as negative regulators of TGF-β, leading to TGF-β
hyperactivation and GBM aggressiveness. These results
identified a regulatory mechanism that results in sustained
TGF-β activation in human GBM, thereby supporting the
functional and clinical significance of epigenetic events in
cancer progression.
Results
Reduced QKI levels in glioblastoma correlated with
patient prognoses
QKI reduction is associated with the initiation and pro-
gression of glioblastoma [28,33], but its clinical significance
in glioblastoma remains unexplored. Immunoblotting
analysis showed that QKI expression was reduced in all
seven glioblastoma cell lines and in glioblastoma tissues
(n = 12) compared with that in primary NHAs and
normal brain tissues (n = 3) (Figure 1A and B). Further-
more, statistical analysis revealed that QKI levels were
associated with shorter overall survival in patients with
glioblastoma (P = 0.002) (n = 167; Figure 1C). Additionally,we found that QKI expression inversely correlated with
MMP9 (P < 0.001) and VEGF levels (P < 0.05) (Figure 1D).
These data suggest a possible link between QKI reduction
and human glioblastoma progression.
MiR-148a targeted QKI
QKI is located on chromosome 6q26-27, which is fre-
quently deleted in astrocytoma and glioblastoma. Inter-
estingly, integrative analysis using the cBioPortal for
Cancer Genomics (http://cbioportal.org) indicated that
approximately 70% of the QKI gene is not deleted in
glioblastoma (Additional file 1: Figure S1A). Given the
QKI promoter hypomethylation (Additional file 1: Figure
S1B), DNA methylation is unlikely to be the major
mechanism responsible for the downregulation of QKI.
Chen et al found that TP53 regulates QKI directly; how-
ever, most TP53 mutations in glioblastoma do not fea-
ture QKI deletion (Additional file 1: Figure S1C).
Moreover, real-time PCR analysis revealed no appre-
ciable alteration of QKI mRNA expression in glioblast-
oma tissue compared with normal brain tissue
(Additional file 1: Figure S1D), which suggests that the
reduction of QKI protein in glioblastoma is not due to
transcriptional inhibition.
Analysis using three publicly available algorithms
(TargetScan, PicTar, miRanda) revealed that the QKI-3′
UTR contains conserved critical nucleotides that may
serve as a legitimate target of miR-148a (Figure 2A),
which is substantially overexpressed in glioblastoma
[34]. Immunoblotting analysis showed that QKI expres-
sion was decreased in miR-148a–transduced cells and
increased in miR-148a inhibitor–transfected cells com-
pared to the negative control cells (Figure 2B). The
microribonucleoprotein (miRNP) IP assay revealed a
selective association of miR-148a with QKI (Figure 2C).
Ectopically expressing miR-148a had no effect on
GFP–γ-tubulin expression, but robustly inhibited the
expression of GFP with a complete, wild-type QKI-3′
UTR in glioblastoma cells (Figure 2D). Notably, the lu-
ciferase reporter assay showed that miR-148a inhibitor
abolished the inhibitory effect of miR-148a linked with
QKI-3′UTR, whereas miR-148a into which a mutation
had been introduced lost the ability to reduce luciferase
activity despite the presence of QKI-3′UTR (Figure 2E).
Collectively, these results demonstrate that QKI is a
bona fide target of miR-148a.
MiR-148a targeted SKP1 and activated TGF-β signaling
As QKI has been reported as a negative regulator of
TGF-β signaling, we investigated whether miR-148a is
involved in TGF-β activation. TGFβR activation results
in the phosphorylation of specific receptor-activated
Smads (R-Smads), which translocate into the nucleus
and regulate the transcription of target genes [35-37].
Figure 1 Restoration of QKI inhibits glioma tumorigenesis. Western blotting (WB) of QKI in (A) three normal brain tissues and 12 glioma
tissues, and (B) NHAs and seven glioblastoma cell lines. β-Actin was used as the loading control. (C) Kaplan–Meier analysis of QKI expression in
survival of patients with glioblastoma (P = 0.002, log-rank test; n = 167). (D) QKI expression was inversely associated with VEGF and MMP9 expression in
167 clinical glioma specimens. Figures are visualizations of two representative cases and percentages of samples with low or high QKI expression
relative to VEGF or MMP9 levels.
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E3 ubiquitin ligase complex, ROC1-SCFFbw1a, which
consists of ROC1, SKP1, cullin 1 (CUL1), and F-box
protein (Fbw1a) [38]. Interestingly, SKP1 is the theoret-
ical target gene of miR-148a (Figure 3A). As predicted,
ectopic expression of miR-148a in U87 and U138MG
cells decreased SKP1 expression and ROC1-SCFFbw1a
ubiquitination activity (Figure 3B and C). Furthermore,
miR-148a overexpression reduced the luciferase activity
of SKP1-3′UTR in a consistent and dose-dependent
manner, but miR-148a inhibition increased it. However,
transfection of the miR-148a-mut, containing mutations
in the miR-148a seed region, did not decrease the lucif-
erase activity of SKP1-3′UTR (Figure 3D). Taken to-
gether, our results demonstrate that SKP1 is also a bona
fide target of miR-148a in glioblastoma. Furthermore,
miR-148a overexpression increased Smad luciferase
reporter activity of Smad2/3 phosphorylation, while
miR-148a inhibition reduced it (Figure 3E and F). Im-
munoblotting analysis and immunofluorescence (IF)
staining revealed that miR-148a–expressing cells exhib-
ited a marked increase in nuclear Smads, which wasconfirmed by the cellular fraction assays (Figure 3G and
H). Lastly, but no less importantly, analyzing miR-148a
expression and TGF-β–regulated gene signatures via
GSEA of published TCGA patient expression profiles
allowed us to confirm that miR-148a expression levels
were positively correlated with the TGF-β–activated
gene signatures (Figure 3I).
MiR-148a overexpression correlated with glioblastoma
progression
Real-time PCR analysis revealed that miR-148a was
markedly overexpressed in the eight primary glioblast-
oma tissues compared to that of the normal brain tis-
sues, and in the seven glioblastoma cell lines compared
with the NHAs (Figure 4A and B). Consistent with this,
microarray analysis showed that miR-148a was signifi-
cantly upregulated in glioblastoma (Figure 4C). Fur-
thermore, statistical analysis revealed that miR-148a
levels were inversely correlated with survival (P < 0.001,
Figure 4D). Importantly, miR-148a expression also
correlated with the expression of glioblastoma progres-
sion–related gene signatures (Figure 4E), suggesting
Figure 2 miR-148a directly targets QKI. (A) Predicted miR-148a target sequence in QKI-3′UTR and mutant containing three mutated nucleotides in
the seed sequence of miR-148a (miR-148a-mut). (B) WB of QKI expression in negative control 1 (NC1)- or miR-148a–transduced cells or cells transfected
with NC2 or miR-148a inhibitor. β-Actin was used as the loading control. (C) MiRNP IP revealing the association of miR-148a with QKI. MIG6 and GAPDH
were used as positive and negative controls, respectively; 5S rRNA was used as a control for overall expression levels. (D) WB analysis of GFP
expression. (E) Luciferase assay of cells transfected with pGL3-QKI-3′UTR reporter with miR-148a mimic (10 or 50 nM), miR-148a mutant, or
miR-148a inhibitor (20 or 100 nM).
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progression and that its levels are associated with poor
overall survival in patients with glioblastoma.
MiR-148a upregulation augmented glioblastoma
aggressiveness in vitro and in vivo
As glioblastomas are highly angiogenic and generally
kill via invasiveness, we investigated whether miR-
148a could modulate glioblastoma cell angiogenesis
and invasiveness. As shown in Figure 5A and B, miR-
148a overexpression dramatically increased both LN18
and U138MG cell migration and invasiveness. Mean-
while, miR-148a overexpression strongly promoted the
ability of glioblastoma cells to induce vessel formation
(CAM, Figure 5C and D). Moreover, suppressing miR-
148a yielded results to the contrary (Additional file 2:Figure S2A and S2D). Thus, these results support the
view that miR-148a overexpression is linked to glio-
blastoma progression.
The biological role of miR-148a in promoting the
aggressive phenotype of glioblastoma was further
examined in vivo by stereotactically implanting engi-
neered glioblastoma cells into the brains of nude mice.
We used a stable miRNA sponge to inhibit miR-148a
in vivo. Notably, the borders of miR-148a–overexpress-
ing tumors exhibited spike-like structures invading into
the surrounding brain tissues, whereas the control tu-
mors exhibited sharp edges (Figure 6A), indicating that
miR-148a overexpression induced glioblastoma cell inva-
sion into the brain. Meanwhile, IHC and immunoblot-
ting revealed that MMP9 and VEGF expression was
upregulated in miR-148a–overexpressing tumors, while
Figure 3 MiR-148a directly targets SKP1 and activates TGF-β signaling. (A) Predicted miR-148a target sequence in SKP1-3′UTR and mutant
containing three mutated nucleotides in the seed sequence of miR-148a (miR-148a-mut). (B)WB of SKP1 expression in negative control 1 (NC1)- or
miR-148a–transduced cells or cells transfected with NC2 or miR-148a inhibitor. β-Actin was used as the loading control. (C) WB analysis of ubiquitinated
Smad3 (Ub-Smad3) expression. (D) Luciferase assay of cells transfected with pGL3-SKP1-3′UTR reporter with miR-148a mimic (10 or 50 nM), miR-148a
mutant, or miR-148a inhibitor (20 or 100 nM). (E) Smad luciferase reporter activity. (F) WB analysis of p-Smad2, p-Smad3, and Smad/3
expression. (G) WB analysis of Smad2/3 expression in different cellular localizations. (H) IF analysis of Smad2/3 expression. (I) GSEA plot
showing that miR-148a expression correlated positively with TGF-β–activated gene signatures (PLASARI_TGFB1_TARGETS_10HR_UP) in
published TCGA patient gene expression profiles (n = 538).
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uated in miR-148a–inhibited tumors (Figure 6A and
B). More importantly, Kaplan–Meier analysis demon-
strated that mice bearing miR-148a–overexpressing
glioblastomas had significantly shorter survival than con-
trol animals; in contrast, mice bearing miR-148a–inhibited
tumors survived longer than the control mice (Figure 6C).
Taken together, our results suggest that miR-148a in-
duced glioblastoma cell invasiveness and angiogenesis
in vitro and in vivo.QKI and SKP1 played important roles in miR-148a–
induced glioblastoma cell invasiveness and
angiogenesis
In the attempt to understand the role of QKI and
SKP1 repression in miR-148a–induced invasiveness
and angiogenesis, the effects of QKI and SKP1 (with-
out and with the 3′ UTRs) were examined in miR-
148a–overexpressing cells. Co-transfecting QKI or
SKP1 with miR-148a significantly reduced glioblast-
oma cell invasiveness and decreased the ability of
Figure 4 MiR-148a is overexpressed in gliomas. Real-time PCR analysis of miR-148a expression in (A) three normal brain tissues and 12 glioma
tissues, and (B) NHAs and seven glioblastoma cell lines. Transcript levels were normalized to U6 expression. (C) MiR-148a upregulation was
identified in 548 patients from the microarray data using published TCGA data. (D) Correlation between miR-148a levels and survival by
Kaplan–Meier analysis of patients with low (<median, n = 269) or high (>median, n = 269) miR-148a expression. (E) GSEA plot showing that
miR-148a expression correlated positively with glioma progression gene signatures in published TCGA patient gene expression profiles (n = 538). Each
bar represents the mean ± SD of three independent experiments. *P < 0.05.
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(Figure 7A and B). However, combining QKI-3′UTR
or SKP1-3′UTR with miR-148a in the glioblastoma
cells had no obvious effect compared with transfecting
glioblastoma cells with only miR-148a. Taken together,
our results suggest that suppressing QKI and SKP1
plays an important role in miR-148a promotion of in-
vasiveness and angiogenesis.
NF-κB induced miR-148a in glioblastoma
It is notable that miR-148a expression also correlated
with the expression of NF-κB–regulated gene signa-
tures (Additional file 3: Figure S3A). However, ectopi-
cally expressing miR-148a had no effect on the NF-κBluciferase reporter activity (Additional file 3: Figure S3B).
Interestingly, there was a marked increased in miR-
148a expression in glioblastoma cells treated with
tumor necrosis factor-α (TNF-α), whereas TGF-β had
minimal effects on miR-148a expression (Figure 8A).
Importantly, pyrrolidine dithiocarbamate (PDTC, a NF-
κB inhibitor) and a TNF-α–neutralizing antibody pre-
vented the stimulatory effect of TNF-α on miR-148a
(Figure 8B). Analysis of the MIR148A promoter region
using ConSite (http://consite.genereg.net/) predicted
five typical NF-κB–responsive elements (serum re-
sponse elements, SREs; Figure 8C). Chromatin immu-
noprecipitation (ChIP) showed that endogenous NF-κB
proteins significantly bound to the first SRE in the
Figure 5 MiR-148a promotes the aggressive phenotype of glioblastoma cells in vitro. (A) Representative images and quantification of
invading cells analyzed by Transwell matrix penetration assay. (B) Representative images of vector- or miR-148a–transfected glioblastoma cell lines
analyzed by wound healing assay. (C) Representative images of chicken CAM blood vessels stimulated with conditioned medium. (D) Representative images
and quantification of HUVECs cultured on Matrigel-coated plates with conditioned medium from vector- or miR-148a–transfected glioblastoma cell lines.
Wang et al. Molecular Cancer 2015, 14:2 Page 7 of 14
http://www.molecular-cancer.com/content/14/1/2MIR148A promoter (Figure 8C). We also subcloned
the fragment containing the two NF-κB binding sites
into the pGL3 dual luciferase reporter vectors. As
shown in Figure 8D, TNF-α increased the luciferase ac-
tivity. Taken together, our result indicates that the NF-
κB pathway induced miR-148a expression by directly
targeting the MIR148A promoter. Furthermore, Smad
luciferase reporter activity was significantly increased
in TNF-α–treated glioblastoma cells, as expected
(Figure 8E). As shown in Figure 8F, p-Smad2/3 were
also elevated in TNF-α–treated cells, but miR-148a in-
hibitor halted the effect. Moreover, TGF-β–induced
endogenous Smad2/3 activity was prolonged in TNF-
α–treated glioblastoma cells (Figure 8G), which sug-
gests that TNF-α sustained TGF-β–induced TGF-β/
Smad activation in glioblastoma cells. These results in-
dicate that miR-148a was involved in TNF-α–mediated
TGF-β/Smad activation.MiR-148a expression correlated with NF-κB activity and
TGF-β/Smad pathway hyperactivation in clinical
glioblastoma
Lastly, we examined whether activation of the NF-
κB/miR-148a/TGF-β/Smad axis identified in our
glioblastoma cell models would also be evident in
clinical glioblastoma tumors. As shown in Figure 9,
there was positive correlation between the miR-148a
levels in 10 freshly collected glioblastoma samples
with MMP9 (r = 0.674, P < 0.001) and VEGF mRNA
levels (r = 0.748, P < 0.001), the DNA-binding activity
of NF-κB (r = 0.895, P < 0.001), and p-Smad3 expres-
sion (r = 0.754, P = 0.001). These results support the
notion that hyperactive NF-κB signaling induces
miR-148a expression, resulting in TGF-β/Smad path-
way activation and consequently leading to the pro-
motion of malignant phenotypes of glioblastoma and
poor clinical prognosis of clinical glioblastoma.
Figure 7 QKI and SKP1 play important roles in miR-148a promotion of the aggressive phenotypes of glioblastoma. (A) Invaded
glioblastoma cells transfected with different nucleotides. (B) The tube length of glioblastoma cells transfected with different nucleotides.
Figure 6 miR-148a promotes the aggressive phenotype of glioblastoma cells in vivo. (A) H&E and IHC staining showed that miR-148a
overexpression induced the aggressive phenotype of glioblastoma cells in vivo, while miR-148a suppression inhibited it, as indicated by MMP9- and
VEGF-positive cells and glioblastoma cell invasion into the surrounding brain tissues. Figures are representative images of various brain sections from
two independent experiments with five mice per group with similar results. (B) WB analysis of MMP9, VEGF, and QKI expression in brain
tissues. (C) Kaplan–Meier survival of mice (n = 5 per group) inoculated with the indicated cells. Error bars represent the mean ± SD of three
independent experiments. *P < 0.05.
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Figure 8 NF-κB induces miR-148a expression. (A) Real-time PCR analysis of miR-148a expression in glioblastoma cells treated with 10 ng/mL
TNF-α or 100 pM TGF-β for 3 hours. Transcript levels were normalized to U6 expression. (B) Real-time PCR analysis of miR-148a expression in cells
treated with or without PDTC or neutralizing anti–NF-κB antibody (2 μg/mL) for 3 hours. (C) Schematic of typical miR-148a promoter SREs.
Also shown are ChIP assay results for the miR-148a promoter SREs physically associated with NF-κB. ChIP assay results for the SREs of MIR148a
promoter physically associated with NFκB or RNA pol II in indicated cells treated with or without TNF-α (see Supplemental Figure 3). (D) Luciferase assay
of cells transfected with the pGL3-SRE reporter treated with or without TNF-α. (E) Smad luciferase reporter activity in cells treated with or without TNF-α
for 3 hours (F) WB of p-Smad2, p-Smad3, Smad2/3, and IκBα in TNF-α–treated cells (10 ng/mL) in response to treatment with control. (G) In vitro kinase
assay indicating that TGF-β–induced endogenous Smad activity was prolonged in TNF-α–treated cells, which the miR-148a inhibitor abrogated. Error bars
represent the mean ± SD of three independent experiments. *P< 0.05.
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The key finding of the present study is that NF-κB in-
creases miR-148a expression to sustain the TGF-β/Smad
signaling pathway by downregulating QKI and SKP1.
We demonstrate that NF-κB binds directly to the miR-
148a promoter to regulate miR-148a expression.
Furthermore, QKI and SKP1 are bona fide targets ofmiR-148a. QKI and SKP1 inhibition led to the induction
of TGF-β/Smad signaling activity. Ectopic miR-148a ex-
pression dramatically promoted glioblastoma aggressive-
ness both in vitro and in vivo. Importantly, the
significant correlation detected among miR-148a levels,
NF-κB, and TGF-β/Smad signaling hyperactivation was
confirmed in a cohort of human glioblastoma samples.
Figure 9 Clinical relevance of the NF-κB/miR-148a/TGF-β/Smad axis in human glioblastoma. Expression and correlation of miR-148a with
MMP9 and VEGF mRNA expression, p-Smad3 expression, and NF-κB activity (detected by an EMSA assay) in 10 human glioblastoma samples.
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sents a critical mechanism for promoting glioblastoma
aggressiveness.
QKI is a tumor suppressor in several cancers, includ-
ing oral cancer, prostate cancer, colorectal cancer, gastric
cancer, and brain cancer [28,39-42]. However, the bio-
logical effect of QKI on cancer development and pro-
gression remains unclear. In the present study, statistical
analysis of clinical specimens revealed, for the first time,
that QKI is associated with shorter overall survival of pa-
tients with glioblastoma, supporting the notion that QKI
functions as a tumor suppressor. In addition to the gen-
ome mutations or deletions that can lead to QKI down-
regulation [27], the loss of QKI expression can also be
regulated at the transcriptional level. For example, TP53
regulated QKI expression in glioma cells by directly tar-
geting its promoter [29]. However, the present study
found no appreciable alteration of QKI mRNA expres-
sion in glioblastoma tissues compared with normal brain
tissues, which intimates that translational repression
might regulate the loss of QKI expression in glioblast-
oma. Analyses using publicly available algorithms and
the present results identified QKI as a direct target of
miR-148a in glioblastoma.
Interestingly, we found that NF-κB activation in-
creased the expression of miR-148a, whose promoter
contains NF-κB target elements. From the above results,
we conclude that NF-κB signaling is probably hyperacti-
vated in glioblastoma, thereby inducing miR-148a ex-
pression but reducing QKI expression. In fact,
hyperactive signaling correlates with glioma progression
and poor prognosis of patients with malignant glioma
[43-46]. Thus, the present study uncovers a novel mech-
anism that regulates QKI expression in glioblastoma.
Despite therapeutic advancements, treating malig-
nant glioma remains a challenge due to ineffective tar-
geting of infiltrating glioma cells and the formation of
abnormal, dysfunctional tumor vasculature [11,47,48].
TGF-β signaling is highly active in glioblastoma, andelevated TGF-β activity has been associated with poor
clinical outcome in this disease [49]. The TGF-β/Smad
pathway is considered a therapeutic target in glioma
[50,51]. QKI suppresses TGF-β signaling in glioblastoma,
and SKP1 is an essential component of the E3 ubiquitin
ligase complex ROC1-SCFFbw1a, which induces Smad3
ubiquitination. As both QKI and SKP1 are bona fide
targets of miR-148a, we suspect that miR-148a is in-
volved in TGF-β activation. We found that miR-148a
enhances the strength and prolongs the duration of
TGF-β/Smad signaling. Via TCGA database analysis,
we found that miR-148a was significantly associated
with shorter overall survival in patients with glioblast-
oma, and correlated positively with TGF-β/Smad sig-
naling activity (P < 0.05). These findings suggest that
miR-148a expression could be sufficient for activating
TGF-β/Smad signaling.
TGF-β and inflammatory cytokines such as TNF-α
and IL-1β are mutually inhibitory. Curiously, the NF-
κB and TGF-β signaling pathways are both hyperactive
in glioblastoma. Focusing on this issue, Song et al. re-
ported that TGF-β induced miR-182 to sustain NF-κB
activation in glioma subsets [18]. However, they did
not clarify the sustained activation of TGF-β. Sustained
activation of regulatory programs requires orchestrated
transcription and post-transcriptional regulation of
gene expression. Due to their multi-targeting proper-
ties and the network effect, miRNAs are perfectly
suited to the task. Here, we showed that miR-148a dir-
ectly repressed QKI and SKP1, which inhibited the
TGF-β pathway. Interestingly, we also found that NF-
κB induced miR-148a expression. Thus, it is plausible
that miR-148a modulates NF-κB–mediated TGF-β ac-
tivation through multiple mechanisms. On the other
hand, analysis of the TCGA datasets indicated that
miR-148a promotes glioblastoma aggressiveness. These
observations indicate that further investigation of the
effect of miR-148a on the TGF-β pathway in glioblast-
oma is warranted.
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In summary, the present study provides an important
link between NF-κB and TGF-β signaling via miR-148a
in glioblastoma. Our findings suggest an essential role of
miR-148a in regulating GBM cell progression. Under-
standing the precise role played by miR-148a in GBM
progression will not only increase our knowledge of the
pathogenesis of gliomas, but also will enable the devel-
opment of novel therapeutic strategies and the identifi-
cation of an effective biomarker for predicting outcomes
for patients with malignant gliomas.
Materials and methods
Cell lines
Primary normal human astrocytes (NHAs) were pur-
chased from ScienCell Research Laboratories (Carlsbad,
CA, USA) and cultured according to the manufacturer’s
instructions. Glioma cell lines A172, T98G, LN18,
LN229, U138MG, U87, and U118MG were from ATCC
(Manassas, VA, USA). The cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum.
Plasmids, virus production, and target cell infection
The human MIR148A gene was PCR-amplified from
genomic DNA and cloned into a pMSCV-puro retroviral
vector. MiR-148a sponge was constructed by annealing,
purifying, and cloning oligonucleotides containing six
tandem “bulged” miR-148a–binding motifs into the
pMSCV vector. Negative control 1(NC1) is a chemically
synthesized double-stranded small RNA used as negative
control for miR-148a mimic. NC2 is a chemically syn-
thesized single-stranded RNA molecule used as negative
control for miR-148a inhibitor. Both of these negative
control molecules exhibit minimum homology to any
human, mouse or rat miRNAs annotated in the current
released of the miRBase database, and no significant
homology to the genomes of those three species as
established by sequence alignment. Human QKI and
SKP1 (S-phase kinase–associated protein 1) were PCR-
amplified from NHA complementary DNA (cDNA) and
cloned into the pMSCV vector. The 3′ UTRs of the hu-
man QKI (QKI-3′UTR) and SKP1 (SKP1-3′UTR) genes,
generated by PCR amplification from NHAs, were
cloned into the SacI/XmaI sites of pGL3 luciferase re-
porter plasmid (Promega, Madison, WI, USA) and
pEGFP-C3 vector (Clontech, Mountain View, CA USA).
The pNF-κB-luc, pSMAD-luc, and control plasmids
(Clontech) were used to determine NF-κB and TGF-β/
Smad signaling activity. Plasmid transfection was per-
formed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Stable cell lines expressing miR-148a and miR-148a
sponge were generated via retroviral infection usingHEK293T cells as described by Li et al. [52] and selected
with 0.5 μg/mL puromycin for 10 days.
Tissue specimens and patient information
A total 167 paraffin-embedded, archived clinical glioma
specimens comprising World Health Organization
(WHO) grade I–IV tumors and 12 freshly snap-frozen
glioma tissues were histopathologically diagnosed at the
Third Affiliated Hospital of Sun Yat-sen University from
2000 to 2010. Normal brain tissues were obtained from
individuals who had died in traffic accidents and who
were confirmed to be free of any preexisting pathologic-
ally detectable conditions. Prior donor consent and ap-
proval from the Institutional Research Ethics Committee
were obtained.
Western blotting analysis
Cells and tissues were harvested in sampling buffer
[62.5 mmol/L Tris-HCl (pH 6.8), 10% glycerol, 2% so-
dium dodecyl sulfate (SDS)] and heated for 5 minutes
at 100°C. Protein concentration was determined with
the Bradford assay using a commercial kit purchased
from Bio-Rad Laboratories (Hercules, CA, USA). Equal
quantities of protein were separated electrophoretically
on 10% SDS/polyacrylamide gels and transferred onto
polyvinylidene difluoride membranes (Roche, Basel,
Switzerland). The membranes were probed with diluted
antibody. The expression of target proteins was deter-
mined with horseradish peroxidase–conjugated anti-rabbit
immunoglobulin G (IgG)/anti-mouse IgG (Sigma-Aldrich,
St Louis, MO, USA) and enhanced chemiluminescence
(Pierce, Rockford, IL, USA) according to the manufac-
turers’ suggested protocols. The membranes were
stripped and reprobed with an anti–β-actin mouse
monoclonal antibody (Sigma-Aldrich) as a loading
control. The related antibodies were anti-Smad2/3,
anti–NF-κB inhibitor (IκBα), anti–matrix metallopro-
teinase 9 (MMP9), anti–phosphorylated (p)-Smad2,
anti–p-Smad3, anti-Smad2, anti–vascular endothelial
growth factor (VEGF) (Cell Signaling Technology,
Beverly, MA, USA), anti-QKI, and anti–green fluores-
cent protein (GFP) (Abcam, Cambridge, MA, USA).
Immunohistochemistry
Immunohistochemical (IHC) analysis was performed to
study altered protein expression in 167 clinical glioma
tissue sections. In brief, paraffin-embedded specimens
were cut into 4-μm sections and baked at 65°C for 30 mi-
nutes. The sections were deparaffinized with xylenes and
rehydrated. Sections were submerged in EDTA antigenic
retrieval buffer and microwaved for antigen retrieval.
The sections were treated with 3% hydrogen peroxide in
methanol to quench the endogenous peroxidase activity,
followed by incubation with 1% bovine serum albumin
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bated with antibody overnight at 4°C. After washing, the
tissue sections were treated with biotinylated anti-rabbit/
mouse secondary antibody (Zymed, San Francisco, CA,
USA), followed by incubation with streptavidin–horse-
radish peroxidase complex (Zymed). The tissue sections
were immersed in 3-amino-9-ethyl carbazole and coun-
terstained with 10% Mayer’s hematoxylin, dehydrated,
and mounted in Crystal Mount (Biomeda, Foster City,
CA, USA).
RNA extraction and real-time quantitative PCR
Total miRNA from cultured cells and fresh surgical glio-
blastoma tissues was extracted using a mirVana miRNA
Isolation Kit (Ambion, Foster City, CA, USA) according
to the manufacturer’s instructions. We synthesized
cDNA using a TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA, USA) and
quantified miR-148a expression using a miRNA-specific
TaqMan MiRNA Assay Kit (Applied Biosystems). Real-
time PCR was performed using the Applied Biosystems
7500 Sequence Detection System. MiRNA expression
was defined based on the comparative threshold (Ct);
relative expression levels were calculated as 2 − (Ct miR-
148a −Ct U6) after normalization with reference to the
quantification of U6 small nuclear RNA expression.
Microribonucleoprotein immunoprecipitation assay
Cells were cotransfected with a plasmid that encodes
hemagglutinin-tagged (HA)-Ago1 and miR-148a (100
nM), followed by HA-Ago1 immunoprecipitation (IP)
using an anti-HA antibody. Real-time PCR analysis of
the IP material was used to test the association of
QKI, mitogen-inducible gene 6 (MIG6), SKP1, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA with the RNA-induced silencing complex.
Luciferase assay
Cells (3 × 103) were seeded in triplicate in 48-well plates
and allowed to settle for 24 hours. Luciferase reporter
plasmids (100 ng) or 100 ng control luciferase plasmid
plus 1 ng pRL-TK Renilla plasmid (Promega) were
transfected into glioblastoma cells using Lipofectamine
2000 (Invitrogen). Luciferase and Renilla signals were
determined 24 hours after transfection using a Dual
Luciferase Reporter Assay Kit (Promega).
Cell invasion assay
Glioblastoma cells (2 × 104) were plated on the top side
of a polycarbonate Transwell filter (with Matrigel) in
the top chamber of a BioCoat Invasion Chamber (BD
Biosciences, Bedford, MA, USA) and incubated at 37°C
for 22 hours; cells in the top chamber were removed
with cotton swabs. Cells that had migrated and invadedto the lower membrane surface were fixed in 1% para-
formaldehyde, stained with hematoxylin, and counted
under a microscope (10 random fields per well, ×100
magnification). The cell counts were expressed as the
mean number of cells per field.
Human umbilical vein endothelial cell tubule formation
assay
Matrigel (200 μL; BD Biosciences) was pipetted into
each well of a 24-well plate and polymerized for 30 mi-
nutes at 37°C. Human umbilical vein endothelial cells
(HUVECs) (2 × 104) in 200 μL conditioned medium were
added to each well and incubated at 37°C in 5% CO2 for
20 hours. Photographs were captured under a × 100
bright-field microscope, and the capillary tubes were
quantified by measuring the total lengths of the com-
pleted tubule structure. Each condition was assessed at
least in triplicate.
Chorioallantoic membrane assay
Chorioallantoic membrane (CAM) assay was performed
using fertilized, day 6 chicken eggs (Yueqin Breeding Co.
Ltd., Guangdong, China). A 1-cm wide window was
opened on the egg shell and the surface of the dermic
sheet on the floor of the air sac was removed to expose
the CAM. A 0.5-cm wide filter paper was first placed on
top of the CAM, and 100 μL conditioned medium was
added to the center of the paper. After closing the win-
dow with sterile adhesive tape, the eggs were incubated
at 37°C in 80–90% relative humidity for four days.
Following fixation with stationary solution (methanol:
acetone = 1:1) for 15 minutes, the CAMs were cut and
harvested and gross photos of each CAM were taken
with a digital camera. The effect of conditioned media
harvested from different cultured cells was evaluated
based on the number of second- and third-order vessels.
Intracranial brain tumor xenografts, IHC, and
hematoxylin–eosin staining
Glioblastoma cells (5 × 105) were stereotactically im-
planted into the brains of nude mice (n = 5 per group).
The mice were monitored daily and euthanized when
moribund. Whole brains were removed, paraffin-
embedded, sectioned into 4-μm thick slides, and stained
with hematoxylin–eosin (H&E) or with anti-QKI
(Abcam), anti-MMP9 (Cell Signaling Technology), or
anti-VEGF (Cell Signaling Technology) antibodies.
Images were captured using an AxioVision Rel. 4.6 com-
puterized image analysis system (Zeiss, Jena, Germany).
Chromatin immunoprecipitation
Cells (2 × 106) in a 100-mm culture dish were treated with
1% formaldehyde to cross-link proteins to DNA. The cell
lysates were sonicated to shear DNA to 300–1000-bp
Wang et al. Molecular Cancer 2015, 14:2 Page 13 of 14
http://www.molecular-cancer.com/content/14/1/2fragments. Equal aliquots of chromatin supernatant
were separated and incubated with 1 μg anti–NF-κB
(Cell Signaling Technology) or anti-IgG antibody
(negative control; Millipore, Billerica, MA, USA) over-
night at 4°C with rotation. After reverse cross-linking
of protein/DNA complexes to free the DNA, PCR was
performed using specific primers.
Electrophoresis mobility shift assay
Electrophoresis mobility shift assay (EMSA) was per-
formed using a LightShift Chemiluminescent EMSA Kit
(Pierce). The following DNA probes containing specific
binding sites were used: NF-κB sense, 5′-AGTTGAGGGG
ACTTTCCCAGGC-3′; NF-κB anti-sense, 5′-GCCTGGGA
AAGTCCCCTCAAC-3′.
Microarray data processing and visualization
Microarray data were downloaded from The Cancer
Genome Atlas (TCGA) database (http://cancergenome.nih.
gov/). Gene Set Enrichment Analysis (GSEA) was performed
using GSEA 2.0.9 (http://www.broadinstitute.org/gsea/).
Statistics
All statistical analyses were carried out using the SPSS
16.0 statistical software package (SPSS Inc., Chicago, IL,
USA). The χ2 test was used to analyze the relationship
between QKI expression and clinicopathological charac-
teristics. Bivariate correlations between study variables
were calculated by Spearman’s rank correlation coeffi-
cients. P < 0.05 was considered statistically significant.
Study approval
The Ethical Committee of the Third Affiliated Hospital
of Sun Yat-sen University evaluated and approved the
use of human glioma tissue specimens, and written in-
formed consent was obtained from all participants or
their appropriate representatives. All animal studies were
conducted with the approval of the Sun Yat-sen University
Institutional Animal Care and Use Committee and were
performed in accordance with established guidelines.
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Additional file 1: Figure S1. Reduction of QKI protein in glioblastoma is
not due to transcriptional inhibition. (A) cBioPortal analysis results showing
that approximately 70% of the QKI gene is not deleted in glioblastoma. (B)
cBioPortal analysis results showing that DNA methylation is unlikely to be the
major mechanism responsible for the downregulation of QKI. (C) cBioPortal
analysis results showing that most TP53 mutations in glioblastoma do not
feature QKI deletion. (D) Real-time PCR of QKI in 3 normal brain tissues and
12 glioma tissues.
Additional file 2: Figure S2. Inhibit miR-148a suppresses aggressive
phenotype of glioblastoma cells in vitro. (A) Representative images and
quantification of invaded cells analyzed using a Transwell matrix penetration
assay. (B) Representative images of NC-2– or miR-148a inhibtor–transfected
glioblastoma cell lines analyzed in a wound healing assay. (C) Representativeimages of chicken chorioallantoic membrane blood vessels stimulated with
conditioned medium. (D) Representative images and quantification of
HUVECs cultured on Matrigel-coated plates with conditioned medium from
NC-2– or miR-148a inhibitor–transfected glioblastoma cell lines.
Additional file 3: Figure S3. miR-148a expression correlated with the
expression of NF-κB–regulated gene. (A) GSEA plot showing that miR-148a
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in published TGCA patient gene expression profiles (n = 538).
(B) Luciferase-reporter NF-κB activity in the indicated cells. (C, D) ChIP
assay results for the SREs of MIR148a promoter physically associated with
NFκB or RNA pol II in indicated cells treated with or without TNF-α. Error
bars represent mean ± SD from 3 independent experiments. *P < 0.05.
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